TY - JOUR
T1 - Infectious complications of purine analog therapy
AU - Samonis, George
AU - Kontoyiannis, Dimitrios P.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2001
Y1 - 2001
N2 - Patients with lymphoid malignancies such as chronic lymphocytic leukemia, particularly those who receive the newer purine analogs, are at increased risk for infectious morbidity and mortality. Defects in cell-mediated immunity appear to be a major predisposing factor in these patients. An expanding spectrum of pathogens associated with lymphocytopenia and depletion of CD4 has been described in the setting of therapy with purine analogs. During the past 2 years new knowledge about the immunosuppression related to that treatment has continued to accumulate.
AB - Patients with lymphoid malignancies such as chronic lymphocytic leukemia, particularly those who receive the newer purine analogs, are at increased risk for infectious morbidity and mortality. Defects in cell-mediated immunity appear to be a major predisposing factor in these patients. An expanding spectrum of pathogens associated with lymphocytopenia and depletion of CD4 has been described in the setting of therapy with purine analogs. During the past 2 years new knowledge about the immunosuppression related to that treatment has continued to accumulate.
UR - http://www.scopus.com/inward/record.url?scp=0034914784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034914784&partnerID=8YFLogxK
U2 - 10.1097/00001432-200108000-00002
DO - 10.1097/00001432-200108000-00002
M3 - Review article
C2 - 11964857
AN - SCOPUS:0034914784
SN - 0951-7375
VL - 14
SP - 409
EP - 413
JO - Current opinion in infectious diseases
JF - Current opinion in infectious diseases
IS - 4
ER -